Tumour Immunology and Anti-Cancer Immunotherapy Unit France
Research
Date range: 1 December 2020 - 30 November 2021
Region: Global
Subject/journal group: All
The table to the right includes counts of all research outputs for Tumour Immunology and Anti-Cancer Immunotherapy Unit published between 1 December 2020 - 30 November 2021 which are tracked by the Nature Index.
Hover over the donut graph to view the Share for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.
Note: Articles may be assigned to more than one subject area.
Count | Share |
---|---|
8 | 0.28 |
Outputs by subject (Share)
Subject | Count | Share |
---|---|---|
Life Sciences | 8 | 0.28 |
Share output for the past 5 years
2016 | 2017 | 2018 | 2019 | 2020 |
---|---|---|---|---|
0.66 | 0.30 | 0.46 | 0.23 | 0.38 |
Compare Tumour Immunology and Anti-Cancer Immunotherapy Unit with other institutions
Collaboration
Date range: 1 December 2020 - 30 November 2021
International vs. domestic collaboration by Share
- 48.68% Domestic
- 51.32% International
Hover over the graph to view the percentage of collaboration.
Top 10 domestic collaborators with Tumour Immunology and Anti-Cancer Immunotherapy Unit by Share (67 total)
-
Tumour Immunology and Anti-Cancer Immunotherapy Unit and Institute Gustave-Roussy (IGR)
(0.98)
-
Tumour Immunology and Anti-Cancer Immunotherapy Unit and National Institute for Health and Medical Research (INSERM)
(0.63)
-
Tumour Immunology and Anti-Cancer Immunotherapy Unit and Ligue Contre Le Cancer
(0.55)
-
Tumour Immunology and Anti-Cancer Immunotherapy Unit and University of Paris-Saclay
(0.55)
-
Tumour Immunology and Anti-Cancer Immunotherapy Unit and University of Paris-Sud (UPSud)
(0.41)
-
Tumour Immunology and Anti-Cancer Immunotherapy Unit and French National Centre for Scientific Research (CNRS)
(0.36)
-
Tumour Immunology and Anti-Cancer Immunotherapy Unit and National Institute for Research in Computer Science and Control (INRIA)
(0.24)
-
Tumour Immunology and Anti-Cancer Immunotherapy Unit and Institut d'Optique Graduate School (IOGS)
(0.21)
-
Tumour Immunology and Anti-Cancer Immunotherapy Unit and CentraleSupélec
(0.21)
-
Tumour Immunology and Anti-Cancer Immunotherapy Unit and Institut des Hautes Études Scientifiques (IHÉS)
(0.21)
Top 10 international collaborators with Tumour Immunology and Anti-Cancer Immunotherapy Unit by Share (80 total)
-
Tumour Immunology and Anti-Cancer Immunotherapy Unit and Agency for Science, Technology and Research (A*STAR)
(1.53)
-
Tumour Immunology and Anti-Cancer Immunotherapy Unit and National University of Singapore (NUS)
(0.81)
-
Tumour Immunology and Anti-Cancer Immunotherapy Unit and Duke-NUS Medical School
(0.78)
-
Tumour Immunology and Anti-Cancer Immunotherapy Unit and The University of Texas MD Anderson Cancer Center
(0.67)
-
Tumour Immunology and Anti-Cancer Immunotherapy Unit and Singapore Health Services Pte. Ltd. (SingHealth)
(0.61)
-
Tumour Immunology and Anti-Cancer Immunotherapy Unit and Duke University
(0.47)
-
Tumour Immunology and Anti-Cancer Immunotherapy Unit and National University Health System (NUHS)
(0.38)
-
Tumour Immunology and Anti-Cancer Immunotherapy Unit and University of New South Wales (UNSW Sydney)
(0.28)
-
Tumour Immunology and Anti-Cancer Immunotherapy Unit and Garvan Institute of Medical Research
(0.26)
-
Tumour Immunology and Anti-Cancer Immunotherapy Unit and Karolinska Institute (KI)
(0.23)
Relationships
Partner Institutions
Tumour Immunology and Anti-Cancer Immunotherapy Unit is a research collaboration whose article contributions are accrued to its participating partner institutions below.

Numerical information only is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.